Clinical Trials Logo

Carotid Artery Disease clinical trials

View clinical trials related to Carotid Artery Disease.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT01597453 Active, not recruiting - Clinical trials for Cardiovascular Disease

NOR-SYS: The Norwegian Stroke in the Young Study

NOR-SYS
Start date: September 2010
Phase: N/A
Study type: Interventional

NOR-SYS is a clinical research program about young ischemic stroke patients from 15 to 60 years. Patients, partners and the couple´s adult children who are at least 18 years old, are all invited to ultrasound examinations due to a standardized protocol. Parents of patients and partners are invited to return their answers of standardized questionnaires about clinical ischemic events such as stroke, angina or myocardial infarction or peripheral artery disease. Study inclusion time of patients and their families is 5 years. A biobank is build from samples from patients, partners and adult children. Clinical follow-ups for patients and partners are planned after 5, 10 and 15 years. Clinical follow-ups for adult children are planned after 10 and 20 years. Hypotheses: What do patients know about their parents clinical ischemic events? How much established pathology in arteries do we find by a standardized ultrasound protocol at the time of ischemic stroke at a young age? Differences concerning risk factors and ultrasound findings between patients and partners? Differences between children from families with several ischemic events among parents and grandparents vs. children from families without ischemic events? Biochemical markers related to ultrasound findings and artery disease.

NCT ID: NCT01445613 Active, not recruiting - Stroke Clinical Trials

Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy

CANOPY
Start date: October 2011
Phase: N/A
Study type: Interventional

The objective of the CANOPY trial is to assess the continued safety and effectiveness of the RX Acculink Carotid Stent System under commercial use in subjects at standard risk for adverse events from Carotid Endarterectomy (CEA) enrolled by physicians with a range of carotid stenting experience.